OOIR: Observatory of International Research

Papers

(The median citation count of Diabetes Technology & Therapeutics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes	171
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE	149
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not	98
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials	95
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies	72
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial	67
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes	63
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial	62
Letter: Response to: “Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia”	62
New Insulins, Biosimilars, and Insulin Therapy	62
Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening	62
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study	61
Acknowledgment of Reviewers 2025	61
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems	60
Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes	57
WITHDRAWN: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial	56
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study	56
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data	56
A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes	55
A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System	55
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes	53
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor	51
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial	50
MiniMed ^TM 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with C	50
Glucose Predictions Improve Glycemic Control: A Digital Twin Evaluation	49

MiniMed ^™ 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvan	47
Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review	43
Beyond the Coefficient of Variation: Reframing Glycemic Variability as Dispersion and Volatility	43
A Retrospective Real-Life Study to Compare Glycemic Control Between Simplified Meal Size Estimation and Precise Carbohydrates Counting in Type 1 Diabetes Patients Using DBLG1 Hybrid Closed-Loop System	42
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes	41
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States	39
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes	38
Metabolic Models, in Silico Trials, and Algorithms	38
Practical Considerations and Implementation of Automated Insulin Delivery Systems	38
The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes	37
Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop	36
Acknowledgment of Reviewers: 2024	35
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy	33
Algorithm-Driven Initiation and Adaptation of Hybrid Closed-Loop in Young Children with Type 1 Diabetes: A Pilot Study	33
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin	33
Dosing Afrezza: It’s Not that Complicated	33
Insulin Replacement Across the Menstrual Cycle in Women with Type 1 Diabetes: An In Silico Assessment of the Need for Ad Hoc Technology	33
The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes	32
Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contributio	32
Current Status and Emerging Options for Automated Insulin Delivery Systems	32
Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial	32
Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges	32
Optimizing Diabetes Management During Type 1 Diabetes Pregnancy with Automated Insulin Delivery Therapy: Clinical Impact and Economic Consequences in Spain	31
RESCUE Collaborative Community: A New Initiative to Reduce Rates of Intended Self-Injury and Suicide Among People with Diabetes	31
A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes	31
Cost–Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes	31
Carbohydrate Counting/Bolus Calculator Mobile Application Improves Time in Range in Adults with Type 1 Diabetes Subjects	30
Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts	30
Accuracy of Dexcom G6 Pro and G7 Continuous Glucose Monitors in Patients Treated with Maintenance Dialysis	30
Letter: Use of an Advanced Hybrid Closed-Loop Insulin Delivery System in a Hemodialysis Patient with Type 1 Diabetes and Anorexia Nervosa: A Case Report	30
Age-Dependent Bolus Settings: Insulin-to-Carbohydrate Ratios and Insulin Sensitivity Factors in Pediatric Patients with Type 1 Diabetes on Conventional CSII in the DPV Registry	30
Composite Metric of Glycemic Control Q-Score Is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients	29
Use of Diabetes Technology at the Advanced Age	29
Online Classification of Unstructured Free-Living Exercise Sessions in People with Type 1 Diabetes	29
Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy	29
FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin	29
Mediating Effects of Technology-Based Therapy on the Relationship Between Socioeconomic Status and Glycemic Management in Pediatric Type 1 Diabetes	29
Hybrid Closed Loop Systems Improve Glycemic Control and Quality of Life in Historically Minoritized Youth with Diabetes	29
Feasibility of Using a Factory-Calibrated Continuous Glucose Monitoring System to Diagnose Type 2 Diabetes	28
Contrasting Glycemic Outcomes in Young People with Diabetic Ketoacidosis at Onset of Type 1 Diabetes	28
Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study	28
Late Afternoon Vigorous Exercise Increases Postmeal but Not Overnight Hypoglycemia in Adults with Type 1 Diabetes Managed with Automated Insulin Delivery	28
Technologies in Diabetes—the Seventeenth ATTD Yearbook	28
Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys	27
Update on Management of Gestational Diabetes Mellitus and the Role of Continuous Glucose Monitor Technology	27
Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring	27
Continuous and Intermittent Glucose Monitoring in 2024	27
Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears	27
Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations	26
Advances in Exercise and Nutrition as Therapy in Diabetes	26

Time in Tight Range Versus Time in Range for Predicting Diabetic Retinopathy in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections: A Retrospective Longitudinal Study with isCGM Data	26
Technologies in Diabetes—the Sixteenth ATTD Yearbook	26
Review of Monogenic Diabetes: Clinical Features and Precision Medicine in Genetic Forms of Diabetes	26
Diabetes Technology and Therapy in the Pediatric Age Group	26
Diabetes Technology in The Hospital	25
Continuous and Intermittent Glucose Monitoring in 2025	25
Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND Trials	25
Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus	24
A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72	24
Insulin Pump Technology for Patients with Alcoholism: A Dangerous Combination or Worth a Try?	24
Impact of Missing Data on the Accuracy of Glucose Metrics from Continuous Glucose Monitoring Assessed Over a 2-Week Period	24
Anticipated Basal Insulin Reduction to Prevent Exercise-Induced Hypoglycemia in Adults and Adolescents Living with Type 1 Diabetes	24
Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study	24
A Comparison of Continuous Glucose Monitoring Estimated Hemoglobin A1c in Adults with Type 1 or Type 2 Diabetes	22
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc	22
Ranting in 2023: I Can't Make This Up	22
Re-Evaluating Inpatient Prandial Insulin Administration Timing: From Data to Clinical Practice	22
MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks	22
Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States	21
Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes	21
Ketone Profiles in Community-Dwelling Adults with Type 1 Diabetes Using Continuous Ketone Monitoring	21
Letter: Dual Glucose-Ketone Monitoring as a Pump/AID Sick-Day Prevention Standard for Diabetic Ketoacidosis	21
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabet	20
Should We Bury HbA1c?	20
Emerging Trends in MAFLD and MASH	20
Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone	20
A Cure for Type 1 Diabetes: Are We There Yet?	20
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes	20
Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes	20
Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens	20
Primary Care and Diabetes Technologies and Treatments	20
Impact of Missed and Late Meal Boluses on Glycemic Outcomes in Automated Insulin Delivery-Treated Children and Adolescents with Type 1 Diabetes: A Two-Center, Population-Based Cohort Study	19
Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia	19
Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Gl	19
Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment	19
Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost–Utility Analysis in The Netherlands	19
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor	19
ATTD 2025 Invited Speaker Abstracts	19
Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes	18
Primary Care and Diabetes Technologies and Treatments	18
Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting	18
Glucose and Psychosocial Outcomes 12 Months Following Transition from Multiple Daily Injections to Advanced Hybrid Closed Loop in Youth with Type 1 Diabetes and Suboptimal Glycemia	18
Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears: Response to Letter to Editor	18
Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia	18
Frequency of Rebound Hyperglycemia in Adults with Type 1 Diabetes Treated with Different Insulin Delivery Modalities	18
Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm	18
Assessment of Glucose Monitoring Adherence in Medicare Beneficiaries with Insulin-Treated Diabetes	18
Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study	17
Prevalence, Safety, and Metabolic Control Among Danish Children and Adolescents with Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems	17
Safety of Options to “Boost” (Enhancing Insulin Infusion Rates) and “Ease-Off” (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis	17
Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions	17
The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications	17
A Telehealth Program Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap in Nursing Homes for Older Adults with Insulin-Treated Diabetes: The Trescasas Study	17
Transitioning from Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring in Combination with a mHealth App Improves Glycemic Control in People with Type 1 and Type 2 Diabetes	17
Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes	17
Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring–Derived Glycemic Metrics in Hospitalized Inpatients	16
ATTD 2025 Read By Title	16
Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?	16
A Comparison of the Rates of Clock-Based Nocturnal Hypoglycemia and Hypoglycemia While Asleep Among People Living with Diabetes: Findings from the Hypo-METRICS Study	16
Safety and Feasibility of Algorithmic Continuous Glucose Monitoring-Based Titration in People with Type 2 Diabetes Using Insulin Degludec, With or Without Noninsulin Glucose-Lowering Drugs: A 16-Week	16
Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review	16
One-Year Follow-Up of Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free Sensor	15
Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness	15
Virtual Clinics for Diabetes Care	15
The Virtual DCCT #3: Relationship of HbA1c and CGM Metrics with Cardiovascular Outcomes	15
Multivendor Continuous Glucose Monitor Integration into the Electronic Health Record: Real-World Experience of an Academic Pediatric Endocrinology Clinic	15
Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)	15
The Type 1 Diabetes and EXercise Initiative: Predicting Hypoglycemia Risk During Exercise for Participants with Type 1 Diabetes Using Repeated Measures Random Forest	15
Comment on “Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes” by Messer et al.	15
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking	15
Snapshot of CGM Metrics in Adolescents and Adults Achieving Target HbA1c Versus Those Not Meeting Target HbA1c	15
Endocrine Management and Clinical Outcomes in a Cohort of Pediatric Patients Undergoing Total Pancreatectomy with Islet Autotransplantation	15
Biases in Glucose Metrics Are Directly Related to Low Coverage of Continuous Glucose Monitoring: Insights from Diverse Populations	15
Glycemic Responses to Graded Exercise Testing in Adolescents Using Automated Insulin Delivery Systems	15
Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications	14
MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience	14
Recent Improvements in Attainment of the Hemoglobin A1c Target of ≤7.0% Among Adults with Type 1 Diabetes in Ontario: A Retrospective Cohort Study	14
Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes	14
Which Treatment Modalities Are Being Used by Italian Children and Adolescents with Type 1 Diabetes?	14
Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems	14

Artificial Pancreas: The First 20 Years*	14
Temporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical T	14
Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study	14
Virtual Clinics for Diabetes Care	14
Letter: “Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting”	14
Subcutaneous Catheter Type and Wear Duration in Automated Insulin Delivery Systems: Associations with Glycemic Control in Patients Living with Type 1 Diabetes	13
Use of Diabetes Technology at the Advanced Age	13
Advances in Exercise and Nutrition as Therapy in Diabetes	13
Safety of Inhaled Insulin in Adults with Diabetes	13
Assessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections	13
Identifying Continuous Glucose Monitoring Data Using Machine Learning	13
Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System	13
Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen	13
Expert Guidance on Off-Label Use of Hybrid Closed-Loop Therapy in Pregnancies Complicated by Diabetes	13
The Type of Patient Training Does Not Impact Outcomes in the First 90 Days of Automated Insulin Delivery Use	12
Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis	12
Insulin Delivery Hardware: Pumps and Pens	12
Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes	12
Hemorrhagic Shock Associated with a Subcutaneous Insulin Pump Catheter: First Time Reported Side Effect	12
Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial	12
Limitations of Reporting Time Below Range as a Percentage	12
International Consensus of Continuous Glucose Monitor Use in Pharmacological Clinical Trials in Diabetes	12
Real-World Insulin Treatment in Pregnant Women with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System	12
Use of Technologies at the Advanced Age	12
The Advanced Hybrid Closed Loop Improves Glycemia Risk Index, Continuous Glucose Monitoring Index, and Time in Range in Children with Type 1 Diabetes: Real-World Data from a Single Center Study	12
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70–180 mg/dL Versus Time-in-Tight-Range 70–140 mg/dL	12
Machine Learning for Predicting the Risk of Transition from Prediabetes to Diabetes	11
Noninvasive Real-Time Glucose Monitoring Is in the Near Future	11
Continuous Glucose Monitoring and Long-Term Assessment of Islet Function in Autologous Islet Transplantation after Total Pancreatectomy for Neoplasm: Preliminary Insights from a Prospective Study	11
Assessing the Accuracy of Continuous Glucose Monitoring Metrics: The Role of Missing Data and Imputation Strategies	11
Real-World Evaluation of Artificial Intelligence-Based Diabetic Retinopathy Screening Using the Optomed Aurora Handheld Fundus Camera	11
Personalized Hemoglobin A1c Shows Better Correlation with Mean Glucose than Laboratory Hemoglobin A1c in Ugandan Youth with Type 1 Diabetes, but Mean Glucose Is Not Clinically Useful in This Populatio	11
Accuracy of FreeStyle Libre 3 During Moderate-Intensity Continuous Aerobic Exercise at Different Phases of the Menstrual Cycle in Females with Type 1 Diabetes	11
Diabetes Technology in the Hospital	11
Insulin Pump Use and Diabetic Ketoacidosis Risk in Type 1 Diabetes: Secular Trends over Four Decades	11
Impact of Continuous Glucose Monitoring Versus Blood Glucose Monitoring to Support a Carbohydrate-Restricted Nutrition Intervention in People with Type 2 Diabetes	11
Real-World Safety and Effectiveness of U200 Insulin Use in Automated Insulin Delivery Systems in Adolescents and Young Adults with Type 1 Diabetes	11
Impact of Inhaled Insulin Therapy on Hypoglycemia	11
Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins	11
A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts	11
Real-world evidence of off-label use of commercially automated insulin delivery systems compared to multiple daily insulin injections in pregnancies complicated by type 1 diabetes	11
Global Burden of Diabetic Ketoacidosis	11
Impact of Age at Diagnosis and Insulin Delivery Modality on Free-Living Glycemia in Type 1 Diabetes During Periods Associated with Dysglycemia: A Retrospective Analysis of the Type 1 Diabetes Exercise	11
30 Years of Developing Inhaled Insulin	11
Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A De	11
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin	10
Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes	10
Use of an Ultrarapid Acting Insulin Analog with Control-IQ: A Case Report	10
Clinically Similar Clusters of Daily Continuous Glucose Monitoring Profiles: Tracking the Progression of Glycemic Control Over Time	10
Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France	10
Assessment of the Glucose Management Indicator Using Different Sampling Durations	10
Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System	10
Impact of Body Composition and Anemia on Accuracy of a Real-Time Continuous Glucose Monitor in Diabetes Patients on Continuous Ambulatory Peritoneal Dialysis	10
Impact of a Specialized Team in Diabetes on Glucometric Parameters and Efficiency Indicators During Hospital Admission in Medical Units	9
Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study	9
Safe Options for the Treatment of Mothers and Babies with Pregestational Diabetes	9
Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre ^® System Initiation in Some People With Type 2 Diabetes o	9
Long-Term Improvements in Glycemia and User-Reported Outcomes Associated with Open-Source Automated Insulin Delivery Systems in Adults with Type 1 Diabetes in the United Kingdom: A Real-World Observat	9
Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems	9
Overcoming Closed-Loop System Limits: Diluted Insulin Improves Glycemic Control and Reduces Nighttime Hypoglycemia in Toddlers with Low Insulin Requirements	9
Emerging Trends in MASLD and MASH	9
Ranting in 2024: It's Not More of the Same	9
Evaluating Cardiovascular-Kidney-Metabolic Syndrome Knowledge in Large Language Models: A Comparative Study of ChatGPT, Gemini, and DeepSeek	9
Temporal Changes in Hemoglobin A1c and Diabetes Technology Use in DPV, NPDA, and T1DX Pediatric Cohorts from 2010 to 2018	9
Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management	9
Comment on Preechasuk et al.: Switching from Intermittently-Scanned Continuous Glucose Monitoring to Real-Time Continuous Glucose Monitoring with a Predictive Urgent Low Soon Alert Reduces Exposure to	9
Association Between Continuous Glucose Monitoring-Derived Glycemia Risk Index and Albuminuria in Type 2 Diabetes	9
Closed-Loop Insulin Delivery May Help Prevent Metabolic Complications During Bariatric Surgery in Patients with Type 1 Diabetes: A Case Report	9
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems	9
Advances in Exercise and Nutrition as Therapy in Diabetes	9
Point-Counterpoint: The Need for Do-It-Yourself (DIY) Open Source (OS) AID Systems in Type 1 Diabetes Management	9
Glycemia Risk Index as a Novel Metric to Evaluate the Safety of Glycemic Control in Children and Adolescents with Type 1 Diabetes: An Observational, Multicenter, Real-Life Cohort Study	9
Corrigendum to: “Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts”	9
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes	9
Ease of Use of the Reusable DuraTouch Pen Injector in Individuals with Diabetes with and Without Previous Pen Injector Experience: A Handling Study	8
The Associations of Mean Glucose and Time in Range from Continuous Glucose Monitoring with HbA1c in Adults with Type 2 Diabetes	8
Lived Experience of Fully Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes	8
Virtual Clinics for Diabetes Care	8
ATTD 2025 E-Poster Abstracts (EPV151–EPV342)	8
Correction to: Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	8
The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes	8
Advances in Exercise and Nutrition as Therapy in Diabetes	8
The Association of Time-in-Range and Time-in-Tight-Range with Retinopathy Progression in the Virtual Diabetes Control and Complications Trial Continuous Glucose Monitoring Dataset	8
The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes	8
Safety and Glycemic Outcomes During the MiniMed ^TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes	8
Impact of Flash Glucose Monitoring on the Fear of Hypoglycemia Phenomenon in Adults with Type 1 Diabetes	8
Obesity and Diabetes	8
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems	8
Automated Insulin Delivery Is Associated with Reduced Hospital Admissions and Costs for Acute Diabetes Complications in Children with Type 1 Diabetes	8
Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial	8
Regarding: Insulin Infusion Set Failures	8
Automated Insulin Delivery Effects During Driving Among Older Adults with Type 1 Diabetes in a Randomized Trial	8
ChatGPT's Response to the Diabetes Knowledge Questionnaire: Implications for Diabetes Education	8
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations	8
Diabetes Technology in the “Real World”: Expanding Access and Addressing Disparities	8